CYP17A1 Antibody (G-4): sc-376711

CYP17A1 Antibody (G-4) is a mouse monoclonal IgG3 antibody that detects CYP17A1 in human samples through western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). CYP17A1, also known as 17alpha-hydroxylase/17,20-lyase, plays a pivotal role in steroidogenesis by catalyzing the conversion of pregnenolone and progesterone into dehydroepiandrosterone (DHEA) and androstenedione, which are essential precursors for sex steroid synthesis. CYP17A1′s activity is crucial for normal sexual development during fetal growth and puberty, while maintaining hormonal balance in adults. CYP17A1 functions in the mitochondria of steroidogenic tissues, regulated by cyclic adenosine monophosphate (cAMP) levels, highlighting CYP17A1′s significance in the endocrine system. Mutations in the CYP17A1 gene can lead to adrenal hyperplasia type V, a condition disrupting normal sexual differentiation and resulting in severe clinical manifestations such as hypokalemia and hypertension. Anti-CYP17A1 antibody (G-4) serves as an invaluable tool for researchers studying steroid metabolism and related disorders, providing insights into molecular mechanisms underlying adrenal function and sexual development.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CYP17A1 Antibody (G-4) References:

1. CYP17A1 Polymorphisms Are Linked to the Risk of Coronary Heart Disease in a Case-Control Study.  |  Lu, S., et al. 2019. J Cardiovasc Pharmacol. 74: 98-104. PMID: 31356544
2. CYP17A1 and Androgen-Receptor Expression in Prostate Carcinoma Tissues and Cancer Cell Lines.  |  Giatromanolaki, A., et al. 2019. Curr Urol. 13: 157-165. PMID: 31933595
3. CYP17A1 exhibits 17αhydroxylase/17,20-lyase activity towards 11β-hydroxyprogesterone and 11-ketoprogesterone metabolites in the C11-oxy backdoor pathway.  |  van Rooyen, D., et al. 2020. J Steroid Biochem Mol Biol. 199: 105614. PMID: 32007561
4. Effect of Differences in the Microbiome of Cyp17a1-Deficient Mice on Atherosclerotic Background.  |  Künstner, A., et al. 2021. Cells. 10: PMID: 34070975
5. The single-nucleotide polymorphism rs743572 of CYP17A1 shows significant association with polycystic ovary syndrome: a meta-analysis.  |  Xu, X., et al. 2021. Reprod Biomed Online. 43: 941-951. PMID: 34538754
6. Synthesis and Structure-Activity Relationships of Novel Non-Steroidal CYP17A1 Inhibitors as Potential Prostate Cancer Agents.  |  Wróbel, TM., et al. 2022. Biomolecules. 12: PMID: 35204665
7. The Association of CYP17A1, CYP19A1, and SHBG Gene Polymorphisms in Polycystic Ovary Syndrome Susceptibility: A Systematic Review and Meta-Analysis.  |  Xing, C., et al. 2022. Front Physiol. 13: 741285. PMID: 35615684
8. Hydroxylation and lyase reactions of steroids catalyzed by mouse cytochrome P450 17A1 (Cyp17a1).  |  Lee, SG., et al. 2023. J Inorg Biochem. 240: 112085. PMID: 36640554
9. Bulk RNA-sequencing, single-cell RNA-sequencing analysis, and experimental validation reveal iron metabolism-related genes CISD2 and CYP17A1 are potential diagnostic markers for recurrent pregnancy loss.  |  He, YB., et al. 2024. Gene. 901: 148168. PMID: 38244949
10. Luteinizing Hormone Surge-Induced Krüppel-like Factor 4 Inhibits Cyp17A1 Expression in Preovulatory Granulosa Cells.  |  Choi, Y., et al. 2023. Biomedicines. 12: PMID: 38255178

The preferred CYP17A1 antibody is CYP17A1 Antibody (D-12): sc-374244.